Targeting WEE1 and asciminib suppresses ABL-tyrosine kinase inhibitor-resistant chronic myeloid leukemia cells
Abstract Background Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the uncontrolled proliferation of white blood cells. Tyrosine kinase inhibitors (TKIs) are the standard treatment; however, resistance to BCR::ABL1 mutations remains challenging. WEE1, a checkpoint k...
Zapisane w:
| Główni autorzy: | , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Springer
2025-07-01
|
| Seria: | Discover Oncology |
| Hasła przedmiotowe: | |
| Dostęp online: | https://doi.org/10.1007/s12672-025-03036-7 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|